SEARCH

SEARCH BY CITATION

References

  • 1
    Felmingham D, Feldman C, Hryniewicz W et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections Clin Microbiol Infect 2002; 8(Suppl. 2): 1242.
  • 2
    Christiansen K, Carbon C, Cars O. Moving from recommendation to implementation and audit: Part 2. Review of interventions and audit. Clin Microbiol Infect 2002; 8(Suppl. 2): 107128.
  • 3
    Interagency Task Force on Antimicrobial Resistance. Public Health Action Plan to Combat Antimicrobial Resistance. Atlanta: Centers for Disease Control and Prevention, 2001.
  • 4
    Therre H. National policies for preventing antimicrobial resistance—the situation in 17 European countries in late 2000. Euro Surveill 2001; 6: 514.
  • 5
    Alliance for the Prudent Use of Antibiotics. Antibiotic Resistance: Synthesis of Recommendations by Expert Policy Groups. Geneva: World Health Organization, 2001 [ http://www.who.International/emc-documents/antimicrobial_resistance/docs/antibiotics.pdf.
  • 6
    World Health Organization. Global Strategy for the Containment of Antimicrobial Resistance. Geneva: World Health Organization, 2001 [ http://www.who.International.
  • 7
    Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest 2001; 119: 426S30S.
  • 8
    Davey P, Pagliari C, Hayes A. The patient's role in the spread and control of bacterial resistance to antibiotics. Clin Microbiol Infect 2002; 8(Suppl. 2), 4368.
  • 9
    The European Commission. Communication from the Commission on a Community Strategy Against Antimicrobial Resistance, Comm 2001, 333, Vol. I. Brussels: Commission of the European Communities, 2001 [ http://www.europa.eu.int.
  • 10
    Council of the European Union. EU-issued Recommendations on the Prudent Use of Antimicrobial Agents in Human Medicine. Proposal for a Council Recommendation, Comm 2001, 333, Vol. II. Brussels: Council of the European Union, 2001.
  • 11
    Economic and Social Committee. Opinion on the Resistance to Antibiotics as a Threat to Public Health (9 September 1998). Official J Europ Communities 1998; 41(C407): 717.
  • 12
    Consumer Committee. Opinion on Resistance to Antibiotics—a Threat to Public Health (1 March, 1999). [ http://www.europa.eu.International/comm/consumers/policy/committee/cc08_en.html.
  • 13
    European Commission. Opinion of the Scientific Steering Committee Opinion on Antimicrobial Resistance (28 May, 1999). [ http://www.europa.eu.International/comm/food/fs/sc/ssc/out50_en.pdf.
  • 14
    Council of the European Union. Council Resolution of 8 June 1999 on antibiotic resistance. A strategy against the microbial threat. Official J Europ Communities 1999; 41(C195): 13.
  • 15
    Council of the European Union. Council resolution on further action in the framework of the strategy against antimicrobial resistance. Bulletin of the European Union 1999; 12-1999: 1.2.204.
  • 16
    Anonymous. A gift to be used sparingly. Lancet Infect Dis 2001; 1: 1.
  • 17
    European Parliament Committee on the Environment Public Health and Consumer Policy. European Draft Report on the Proposal for a Council Recommendation on the Prudent Usage of Antimicrobial Agents in Human Medicine. Provisional 2001/2164 (COS).
  • 18
    The Copenhagen Recommendations. Conclusions of Responding the European Union Conference on the Microbial Threat. Report from the Invitational EU Conference on the Microbial Threat. Copenhagen. Denmark 9–10 September, 1998. [ http://www.sum.dk/publika/micro98/.
  • 19
    World Health Organization. Report on Infectious Diseases 2000: Overcoming Antimicrobial Resistance. Geneva: World Health Organization, 2000 [ http://www.who.International/infectious-disease-report/ 2000/index.html].
  • 20
    Finch RG, Low DE. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Clin Microbiol Infect 2002; 8(Suppl. 2), 6991.
  • 21
    Bisno AL, Gerber MA, Gwaltney JM, Kaplan EL, Schwartz RH. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clin Infect Dis 1997; 25: 57483.
  • 22
    Bergeron MG, Ke D, Menard C et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000; 343: 1759.
  • 23
    Bergeron MG. Rapid PCR detection of bacteria and their antibiotic-resistance genes: improved management, better treatment and less resistance. Curr Infect Dis Rep 2001; 3: 2012.
  • 24
    Guillemot D, Courvalin P. and the French Working Party to Promote Research to Control Bacterial Resistance. Better control of antibiotic resistance. Clin Infect Dis 2001; 33: 5427.
  • 25
    Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. Clin Microbiol Infect 2002; 8(Suppl. 2), 111.
  • 26
    Health Canada & Canadian Infectious Diseases Society. Controlling antimicrobial resistance. An integrated action plan for Canadians. Can Comm Dis Rep 1997; 23(Suppl. 7): 174.
  • 27
    Standing Medical Advisory Committee. The Path to Least Resistance. London: Department of Health, UK, 1998 [ http://www.doh.gov.uk/smac1.htm.
  • 28
    CDC. Plan for addressing emerging infectious diseases threat: antimicrobial resistance. Atlanta: CDC, 1998 [ http://www.cdc.gov/ncidod/emergplan/antiresist/.
  • 29
    Beilby J, Marley J, Walker D, Chamberlain N, Burke M, FIESTA Study Group. Effect of changes in antibiotic prescribing on patient outcomes in a community setting: a natural experiment in Australia. Clin Infect Dis 2002; 34: 5564.
  • 30
    Kristinsson KG. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microbial Drug Resist 1997; 3: 11723.
  • 31
    Ekdahl K. Limiting the spread of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Microb Drug Resist 1998; 23: 99105.
  • 32
    Seppälä H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 4416.
  • 33
    Choutet P. [Impact of Opposable Medical References (RMO) prescription guidelines for antibiotic prescriptions in ambulatory medicine]. Thérapie 2001; 56: 13942 [in French].
  • 34
    Seppälä H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin resistance in group A streptococci: link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21: 137885.
  • 35
    Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–97). J Antimicrob Chemother 2000; 46: 76773.
  • 36
    Granizo JJ, Aguilar L, Casal J, Dal-Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–97). J Antimicrob Chemother 2000; 46: 95964.
  • 37
    Pihlajamaki M, Kotilainen P, Kaurila T et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001; 33: 4848.
  • 38
    Stephenson J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA 1996; 275: 175.
  • 39
    Kristinsson KG. Modification of prescribers' behavior: the Icelandic approach. Clin Microbiol Infect 1999; 5(Suppl. 4): S437.
  • 40
    Guillemot D, Henriet L, Lecoeur H, Weber P, Carbon C. Optimization of antibiotic use rapidly decreases penicillin resistant Streptococcus pneumoniae (PRSP) carriage: the AUBEPPIN Study. In: Abstracts of the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy, 16–19 December, 2001, Chicago, Illinois: American Society for Microbiology, 2001; 264 (abstract 1527).
  • 41
    Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 36570.
  • 42
    Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxycillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286: 4956.
  • 43
    Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 11526.
  • 44
    Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33: 75762.
  • 45
    Paladino JA. Economic justification of antimicrobial management programs: implications of antimicrobial resistance. Am J Health Syst Pharm 2000; 57(Suppl. 2): 1012.
  • 46
    Carbon C, Bax R. Regulating the use of antibiotics in the community. BMJ 1998; 317: 6635.
  • 47
    Isturiz R, Carbon C. Antibiotic use in developing countries. Infect Control Hospital Epidemiol 2000; 21: 3947.
  • 48
    Chahwakilian P. Politiques d'antibiothérapie à l'échelon national dans divers pays. Rev Pneumol Clin 2000; 1S: 912.